Nail psoriasis as a severity indicator: results from the PsoReal study by I Sch&amp et al.
© 2011 Radtke et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Patient Related Outcome Measures 2011:2 1–6
Patient Related Outcome Measures Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
1
ORiginAL ReseARch
open access to scientific and medical research
Open Access Full Text Article
DOI: 10.2147/PROM.S14861
nail psoriasis as a severity indicator: results  
from the PsoReal study
Marc A Radtke1
Anna K Langenbruch1
ines schäfer1 
Katharina herberger1
Kristian Reich2
Matthias Augustin1
1institute for health services 
Research in Dermatology and 
nursing, University Medical center 
of hamburg-eppendorf, hamburg; 
2Dermatologikum hamburg, germany
correspondence: Marc Alexander Radtke 
institute for health services Research 
in Dermatology and nursing, 
competenzzentrum Versorgungsforschung 
in der Dermatologie, cvderm, 
Universitätsklinikum hamburg-eppendorf, 
Martinistrasse 52, 20246 hamburg, 
germany 
Tel +49 040 741 055 428 
Fax +49 040 741 055 348 
email m.radtke@uke.de
Background: Although nail psoriasis affects a substantial proportion of psoriasis patients and 
causes significant psychologic distress, few epidemiologic data characterizing patients with 
nail involvement are available. The aim of this research was to elucidate differences between 
patients with nail psoriasis and those without any nail involvement, taking quality indicators 
of health care from the patient’s perspective into account.
Methods: In total, 2449 patient members of the Deutscher Psoriasis Bund, the largest patient 
organization for psoriasis in Germany, were interviewed in this nationwide, noninterventional, 
cross-sectional study. Patients with nail psoriasis were compared with patients without any nail 
involvement with regard to gender, age, disease duration, affected body surface area, health-
related quality of life (Dermatology Life Quality Index [DLQI] ED-5D), patient-defined treatment 
benefit, amount of inpatient treatments, disease duration, and numbers of work days lost.
Results: Data from 2449 patients with psoriasis were analyzed. Overall, 44.8% (1078) of 
patients were female, mean age was 57.0 ± 11.7 years, and 72.8% had nail involvement and 
showed higher values for affected body surface area than those without nail involvement 
(8.3% versus 5.6%, respectively; P , 0.004). Health-related quality of life was significantly 
lower in patients with nail psoriasis (DLQI 7.2 versus 5.3; ED-5D 60.1 versus 67.3), who had 
more days off work (9.8 versus 3.3).
Conclusion: Nail involvement is an important symptom of psoriasis and is associated with 
greater disease severity and quality of life impairment. Accordingly, management of psoriasis 
should include a special focus on nail involvement.
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Introduction
Nail involvement is associated with significant physical and psychological consequences 
for a substantial number of psoriasis patients.1 Prevalence data for nail involvement in 
psoriasis vary between 10% and 55%.2–4 The prevalence rises to 70%–80% in cases 
where joint involvement is also present.2,3 The clinical spectrum is very heterogeneous 
depending on involvement of the nail bed, matrix, or folds, and includes pitting, 
grooving, and stippling, as well as discoloration, leukonychia, and onychodystrophy 
ranging to onycholysis.4 Combined nail matrix and nail bed psoriasis can develop in 
cases of very severe inflammation, a possible consequence of which is the formation 
of only parakeratotic, crumbly material by the matrix and bed, a condition referred 
to as “psoriatic crumbly nail”.5 This finding constitutes a risk factor for secondary 
mycotic infections, which can occur in up to 27% of psoriasis patients, and calls for 
more detailed diagnostic tests and therapy adapted to the findings.6 Nail psoriasis is Patient Related Outcome Measures 2011:2 submit your manuscript | www.dovepress.com
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associated with a prolonged duration of psoriasis itself7 
and greater severity of skin and joint involvement, and may 
also be an indicator for the activity of psoriatic arthritis.8 
Both psoriasis and psoriatic arthritis, and by implication, 
psoriatic nail disease, have been considered as autoim-
mune disorders. McGonagle et al9 contributed important 
microanatomic and genetic insights which suggest that 
an aberrant response to tissue stressing of the integrated 
nail-joint apparatus, rather than autoimmunicity, is driving 
the inflammatory process. The nail is functionally linked 
to the distal phalanx and several distal interphalangeal 
joint structures, including extensor tendon fibers and the 
collateral ligaments.10
In a large number of psoriasis patients, skin involvement, 
as well as nail involvement, leads to significant impairment 
of quality of life.11–14 This is due to physical symptoms, psy-
chologic burden, and limitations at work11,12 and at leisure. 
Psoriasis on visible areas of the body may give rise to stig-
matization in everyday life.13 The economic implications of 
nail psoriasis have not previously been the specific subject of 
studies, though individual cost-of-illness studies have drawn 
attention to this problem.14,15
Treatment of nail psoriasis can be challenging for both 
the dermatologist and patient.16 Owing to the slow growth 
of the nail plate, response to therapy can sometimes take 
years. A therapeutic response in the areas of the nail matrix 
and nail bed has been described for vitamin D analogs and 
highly potent topical steroids in liquid form.7,17,19 However, 
the feasibility of topical therapy is limited by the difficulty 
in achieving adequate antipsoriatic concentrations at the 
site of the inflammatory process.18 A faster, better, and more 
sustained response to therapy in nail psoriasis has been 
described for systemic therapeutics and in particular for 
biologics.19–22 In the largest clinical study so far published 
on the systemic treatment of psoriasis, infliximab was found 
to be a highly effective therapy for nail psoriasis over the 
long term.27
Although it can be assumed that nail psoriasis constitutes 
a significant health problem for patients, there have so far 
been only a few studies from Germany in which disease 
severity and quality of life of patients with nail psoriasis 
were examined. The data acquired to date were collected 
via dermatologic centers and clinics,31–33 which may suggest 
selection and response bias.
The aim of this study was to characterize patients with 
nail psoriasis in comparison with patients without any nail 
involvement and to determine profiles of patients with nail 
psoriasis, including quality of life, by collecting relevant data 
from patients of the Deutscher Psoriasis Bund, the largest 
patient organization for psoriasis in Germany.
Materials and methods
study design
This cross-sectional study involved the collection of health 
care-related data by standardized questionnaires. The target 
variables included defined care indicators analogous to those 
of an earlier study (PsoHealth 2007).19 The conception and 
coordination of the study were under the auspices of the 
Competence Centre for Health Services Research in Derma-
tology (University Clinics of Hamburg) in cooperation with 
the Professional Association of German Dermatologists and 
the German Dermatological Society. Ethical approval was 
obtained from the Institutional Review Board.
Recruitment
Patient recruitment was done via the Deutscher Psoriasis 
Bund. Questionnaires were sent to all members of this 
organization as a supplement to the March 2008 edition 
of the PsoMagazine. A total of 6923 questionnaires were 
distributed nationwide. After obtaining informed consent, 
the completed questionnaires were returned to the Compe-
tence Centre for Health Services Research in Dermatology 
by post. Patients were admitted to the study if they were 
suffering from medically verified psoriasis and were at least 
18 years of age.
Variables
Sociodemographic data, health insurance status, case his-
tory of psoriasis and psoriatic arthritis, past and present 
treatments, patient-defined therapeutic benefit, number of 
inpatient treatments for psoriasis in the previous 5 years, 
number of office visits, days off work, and health-related 
quality of life were assessed. The patient filled in a body 
diagram with a box grid to indicate the affected body area. 
Disease-specific (dermatologic) quality of life was mea-
sured using the Dermatology Life Quality Index (DLQI), 
which consists of 10 items. General health-related quality 
of life was determined using the visual analog scale from 
Euroqol (EQ-5D), whereby the patient grades his/her cur-
rent state of health on a scale from 0 (“worst imaginable 
state of health”) to 100 (“best possible state of health”).
statistical analysis
Data entry was performed by means of double entries in 
Excel files using plausibility tests. Congruence of the entries 
was checked by matrix subtraction. In case of discrepancy, Patient Related Outcome Measures 2011:2 submit your manuscript | www.dovepress.com
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an independent coder determined the correct entry using the 
original questionnaires. Results of the survey were   evaluated 
using SPSS Version 17 for Windows. All data were described 
using standard statistical parameters (absolute and percentile 
frequencies for categoric data; mean value, standard devia-
tion for continuous data). Nonparametric Mann-Whitney 
U-tests or unpaired t-tests were carried out to compare 
the results from the different patient groups. Alpha errors 
were adjusted using a Bonferroni correction. Due to the large 
sample size, each t-test was complemented by effect-size 
determination (d) to qualify the mean difference through the 
averaged standard deviation. Effect sizes of 0.2, 0.5, and 0.8, 
respectively, represent weak, medium, and strong effects in 
unpaired t-tests.20
Results
sociodemographic data
Of the 6923 questionnaires distributed, a total of 2489 were 
returned within the study period (35.4%). After exclusion of 
invalid questionnaires, data sets amenable to evaluation were 
available from 2449 (98.4%) patients. The mean age of the 
patients was 57.0 ± 11.7 years (Table 1), 44.8% (n = 1078) 
were female, 52.7% (n = 1289) were in paid work, and 71.1% 
(n = 1740) were married. On average, the initial diagnosis of 
psoriasis had been 34.0 years earlier.
clinical characteristics of patients  
with and without nail psoriasis
Of the patients who responded, 72.8% reported nail 
involvement. The mean duration of psoriasis did not dif-
fer significantly between patients with and without nail 
  psoriasis (34.3 years versus 33.0 years, respectively, Table 2). 
Patients with nail psoriasis reported a significantly greater 
area of affected skin (8.3% versus 5.6% affected body area; 
P , 0.001) and displayed a significantly lower quality of 
life in the DLQI (7.2 versus 5.3; P , 0.001) and a poorer 
state of health in the EQ5-D (60.1 versus 67.3; P , 0.001). 
The number of days off work was significantly higher in 
patients with nail psoriasis (9.8 versus 3.3; P , 0.001). 
Mean   patient-defined therapeutic benefit was slightly higher 
in patients without nail psoriasis (2.4 versus 2.3). Patients 
with nail psoriasis displayed significantly worse values for 
satisfaction with their treatment, stress, and time expenditure 
due to therapy. These differences remained significant even 
after Bonferroni correction. The mean number of consul-
tations was significantly higher in nail psoriasis patients, 
both with dermatologists and with orthopedic surgeons/ 
rheumatologists (Table 3).
Discussion
The aim of the present study was to analyze predefined 
clinical and socioeconomic characteristics of patients with 
nail psoriasis versus patients without nail involvement 
in   Germany. The background of this study is the special 
importance of nail involvement as a stigmatizing factor 
and as a variable in long-term therapy planning.12–15,30 The 
method of direct data collection from patients, who were 
also members of the Deutscher Psoriasis Bund, a self-help 
organization, without approaching their attending doctors, 
was chosen deliberately in order to achieve a patient cohort 
selected differently from the means of data access used in 
previous studies.34 An added benefit of this method was 
the exclusion of bias from “social desirability” of office-
based practice.
The present data allow the hypothesis-generating assump-
tion that nail involvement in psoriasis might be a predictor of a 
more severe course of the disease. The visibility of nail involve-
ment and the associated stigmatization could, moreover, be an 
important determinant of reduced quality of life, although this 
might also be poorer because the body is affected to a much 
greater degree in patients with nail psoriasis.
Table 1 characteristics of study population (n = 2449)
n % Mean age ± SD   
(range 18–92)
Female 1078 44.8 57.0 ± 11.7
Male 1326 55.2 55.5 ± 12.0
Totala 2404 100.0 57.0 ± 11.7
Partnership/marriage 1740 71.1 n.a.
Level of education
Without school  
completion certificate
9 0.4 n.a.
secondary school 619 25.3 n.a.
secondary modern school 738 30.1 n.a.
high school 990 40.4 n.a.
school for special education 2 0.1 n.a.
Other undefined education 48 2.0 n.a.
Working life
employed 1289 52.7 n.a.
not currently working 1159 47.3 n.a.
Current treatment
Biologics 190 7.8 n.a.
systemic treatment  599 24.5 n.a.
Topical steroids 333 13.6 n.a.
Topical vitamin D3 analogs 323 13.2 n.a.
UV treatment 548 22.4 n.a.
PUVA treatment 71 2.9 n.a.
Topical skin care products 460 18.8 n.a.
Notes: aMissing value for gender in 45 patients, missing value for age in 20 patients. 
Abbreviations: PUVA, psoralen combined with ultraviolet A; UV, ultraviolet; n.a., 
not available; sD, standard deviation.Patient Related Outcome Measures 2011:2 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
4
Radtke et al
The data from the present study confirm the results of two 
earlier health care studies conducted in dermatology practices 
in Germany,21,22,30 in which nail involvement in psoriasis was 
likewise associated with more severe forms of the disease, par-
ticularly with regard to the incidence of joint involvement and 
impairment of quality of life.23 In this study, nail psoriasis was 
diagnosed in 40.9% of the patients, and those with nail involve-
ment also had a longer disease duration (21.9 versus 18.1 years), 
higher disease severity (mean   Psoriasis Area Severity Index 
12.7 versus 9.3), higher frequency of psoriatic arthritis (26.0% 
versus 12.7%), more impairment of health-related quality of 
life (mean Dermatology Life Quality Index 8.9 versus 7.3), and 
a 2.5-fold higher rate of inpatient treatment.
Any interpretation of the results must take account of 
the fact that, although a reasonable geographic distribution 
of participating patients was achieved, the possibility that 
patients with a high level of suffering and severe disease 
may actively seek the support of a patient organization such 
as the Deutscher Psoriasis Bund. Thus, selection bias cannot 
be ruled out here. Moreover, the mean age of the patients 
and their duration of disease were significantly higher in the 
present study than in the preceding PsoHealth studies from 
2005 and 2007. The reason for this might be that patients with 
long-standing disease, and all its frustrations, are more likely 
to join a patient organization and to remain members for a 
longer period of time. A further limitation of this approach is 
the lack of differentiation between patients with nail involve-
ment and patients with psoriatic arthritis, who often show 
both disease manifestations at the same time. Data concerning 
work time lost due to psoriasis may not reflect differentiation 
between the different clinical aspects.
There is no doubt that nail involvement in psoriasis con-
stitutes not only a cosmetic problem, but also an important 
part of the complex inflammatory process of psoriasis. The 
importance of this is further underscored by the association 
between nail psoriasis and psoriatic arthritis33 and by the sig-
nificant comorbidity of psoriasis with metabolic syndrome 
and other chronic inflammatory autoimmune diseases.24,25 
Therefore, the aim of future health care studies of nail pso-
riasis should be to examine the extent to which the nature 
and intensity of nail involvement affects quality indicators 
of the severity of psoriasis under “real-world” conditions.
Table 3 Frequency of consultations due to psoriasis (n = 2366)a
No nail psoriasis Nail psoriasis Pc
Mean SD Mean SD
Office visits in last 12 months
Dermatologistb 1.7 1.3 2.0 1.4 ,0.001*
internal specialistb 0.6 0.9 0.8 1.1 ,0.001*
Orthopedic  
surgeon/
rheumatologistb
0.8 1.0 1.1 1.1 ,0.001*
general  
practitionerb
1.9 1.1 2.1 1.2 ,0.001*
Notes: aData with regard to a therapist in those cases in which any office visit 
frequency was entered were counted as “no visits”; n = 52 (no entry regarding a 
doctor); n = 31 (no entry regarding nail involvement); bwithin the last 12 months, 0 = 
no doctor visits, 1 = 1–2 times, 2 = 3–5 times, 3 = 6–10 times, 4 $ 10 times; cdue 
to the ordinal scaled variable a nonparametric Mann-Whitney U-test was calculated; 
*still significant after Bonferroni correction. 
Abbreviation: sD, standard deviation.
Table 2 comparison between psoriasis patients with and without nail involvement (n = 2449)
Variable No nail psoriasis Nail psoriasis Pc dd
n Mean SD Mean SD n
Years since initial diagnosis 607 33.0 16.1 34.3 13.9 1730 0.089 0.08
Affected body area (%) 621 5.5 11.1 8.3 14.9 1753 ,0.001** 0.21
Quality of life (DLQi) 621 5.3 5.3 7.2 6.4 1761 ,0.001*** 0.33
eQ-5D: state of health (0–100) 611 67.3 21.0 60.1 21.6 1747 ,0.001*** 0.34
number of inpatient treatments  
for psoriasis in previous 5 years
95 3.0 4.5 3.5 6.0 442 0.445 0.09
Days off work due to psoriasis in  
previous 12 months
339 3.3 15.9 9.8 42.0 936 ,0.001* 0.2
PBi total score (weighted) 589 2.4 1.1 2.3 1.1 1671 0.004* 0.14
satisfaction with previous  
psoriasis treatmenta
604 2.0 0.8 2.2 0.8 1722 ,0.001* 0.21
Treatment regarded as a burdenb 511 1.8 1.2 2.1 1.2 1534 ,0.001* 0.21
Treatment is associated with  
great time expenditureb
509 1.7 1.3 1.9 1.3 1531 0.001* 0.17
Notes: a(1 = very satisfied to 4 = very unsatisfied); b(1 = not at all to 5 = very); clevel of significance in t-test for independent samples; deffect size; *significant after 
Bonferroni correction at the P , 0.05 level; **highly significant after Bonferroni correction at the P , 0.01 level; ***highly significant after Bonferroni correction at the 
P , 0.001 level. 
Abbreviations: DLQI, Dermatology Life Quality Index; EQ-5D, Euroqol; PBI, patient-defined treatment benefit; SD, standard deviation.Patient Related Outcome Measures 2011:2 submit your manuscript | www.dovepress.com
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Conclusion
Nail involvement is an important symptom of psoriasis and 
is associated with greater disease severity and quality of life 
impairment. Accordingly, management of psoriasis should 
include a special focus on nail involvement. Should the 
results of the present study, albeit at present only hypothesis-
generating, be confirmed, further studies should be conducted 
to determine the extent to which the severity of nail involve-
ment might serve as a predictor for the identification of 
high-need patients. In the event that nail psoriasis proves to 
have predictive value, it could, like psoriatic arthritis, be an 
indicator of need for early systemic therapy to avert serious 
progression of the disease.
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